Today: 25 January 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Hongkong Land Holdings (SGX:H78) Stock on 2 December 2025: Buybacks, Deep Value Discount and 2026 Outlook

Hongkong Land Holdings (SGX:H78) Stock on 2 December 2025: Buybacks, Deep Value Discount and 2026 Outlook

As of the morning of 2 December 2025, Hongkong Land Holdings Limited (SGX:H78) is trading around US$6.57, flat in early trading after a 3.46% surge on 1 December that made it the top performer on Singapore’s Straits Times Index (STI). TradingView The stock has climbed roughly 45% over the last 12 months, supported by aggressive share buybacks and a series…
2 December 2025
···
Marco Polo Marine (SGX:5LY) Stock Soars After 170% Profit Jump – Latest Share Price, Earnings and 2026 Outlook

Marco Polo Marine (SGX:5LY) Stock Soars After 170% Profit Jump – Latest Share Price, Earnings and 2026 Outlook

As of 2 December 2025, Marco Polo Marine Ltd (SGX:5LY), a Singapore-based offshore marine logistics and shipyard group, has become one of the hottest small-cap names on the SGX Mainboard. The stock jumped about 7.5% in Tuesday trading to around S$0.129, after the company reported a 169.7% surge in full-year net profit to S$58.5 million for FY2025 and a four-fold…
2 December 2025
····
Sembcorp Industries (SGX: U96) Stock: Latest Share Price, News and 2025–2026 Outlook as of 2 December 2025

Sembcorp Industries (SGX: U96) Stock: Latest Share Price, News and 2025–2026 Outlook as of 2 December 2025

Singapore – 2 December 2025 Sembcorp Industries share price today Sembcorp Industries Ltd (SGX: U96) is trading around S$6.09 on the Singapore Exchange as of about 09:21 SGT on 2 December 2025, up roughly 0.2% on the day. Beansprout Over the past week the stock has hovered just above S$6.00, with recent historical prices showing a close of S$6.08 on…
2 December 2025
···
City Developments Limited (SGX: C09) Stock Outlook 2026: New London Deal, Analyst Upgrades and Q3 2025 Reset

City Developments Limited (SGX: C09) Stock Outlook 2026: New London Deal, Analyst Upgrades and Q3 2025 Reset

Published: 2 December 2025 City Developments Limited (CDL, SGX: C09) has quietly turned 2025 into a comeback year. As of 1 December 2025, the stock last traded at around S$7.20, after a strong rebound that has lifted year‑to‑date returns to roughly 44%, significantly outperforming the Straits Times Index. CDL Investor Relations On 2 December, the group added fresh momentum with…
2 December 2025
····
Singapore Airlines (SGX:C6L) Stock on 2 December 2025: Dividend Strength vs Air India Drag and 2026 Outlook

Singapore Airlines (SGX:C6L) Stock on 2 December 2025: Dividend Strength vs Air India Drag and 2026 Outlook

Singapore Airlines Limited (SIA, SGX:C6L) enters December 2025 as a classic “good airline, messy earnings story” stock. On 2 December 2025, the flagship carrier is trading around S$6.50 per share, valuing the group at roughly S$20.3 billion. SG Investors The share price sits in the middle of its 52‑week range of S$5.90–S$7.63, after peaking in late July and easing as…
2 December 2025
····
Jardine Matheson Stock (SGX: J36, OTC: JMHLY): Buyback, Mandarin Oriental Deal and New CEO Shape 2026 Outlook

Jardine Matheson Stock (SGX: J36, OTC: JMHLY): Buyback, Mandarin Oriental Deal and New CEO Shape 2026 Outlook

As of 2 December 2025, Jardine Matheson has quietly become one of Singapore’s standout blue chips—up nearly 50% in a year—while it remakes itself from an old‑school conglomerate into a more hard‑nosed investment group. Where Jardine Matheson’s Share Price Stands Today Jardine Matheson Holdings Limited (“Jardine Matheson”) is listed in Singapore (SGX: J36, USD counter) and trades in the US…
2 December 2025
····
Wilmar International (SGX:F34) Stock: Legal Storms, India Bet and 2026 Outlook After a Fresh Downgrade

Wilmar International (SGX:F34) Stock: Legal Storms, India Bet and 2026 Outlook After a Fresh Downgrade

Singapore – 2 December 2025 Wilmar International Limited’s share price is sitting in a very uncomfortable sweet spot: operationally strong, legally embattled, and priced by the market as if both stories might be true at once. On 2 December 2025, Wilmar (SGX:F34, ticker WLIL on some platforms) traded around S$3.22, down about 0.9% on the day, with an intraday range…
2 December 2025
···
ComfortDelGro (SGX: C52) Stock on 2 December 2025: Dividend Giant, Robotaxi Bets and a Market That’s Still Not Fully Convinced

ComfortDelGro (SGX: C52) Stock on 2 December 2025: Dividend Giant, Robotaxi Bets and a Market That’s Still Not Fully Convinced

ComfortDelGro Corporation Limited – the Singapore-listed transport group behind buses, rail and those ubiquitous blue-and-yellow taxis – is quietly in the middle of a big strategic pivot. Revenue and profits are growing, the dividend yield is fat, and the company is betting hard on electric fleets and autonomous vehicles. Yet the share price still trades well below most analyst targets,…
2 December 2025
····
UOL Group Limited (SGX: U14) Stock Outlook 2026: Can the Property Giant Sustain Its 2025 Breakout?

UOL Group Limited (SGX: U14) Stock Outlook 2026: Can the Property Giant Sustain Its 2025 Breakout?

UOL Group Limited’s share price has surged in 2025, riding on strong residential sales, easing interest rates and a broad re-rating of Singapore’s property names. As of 2 December 2025, the stock is trading near its 52‑week high and has become one of the standout blue chips on the Singapore Exchange (SGX). The Smart Investor This article pulls together the…
2 December 2025
····
Live Nation Bets on Feel‑Good, Non‑Alcoholic ‘Social Tonics’ With New Hiyo Partnership

Live Nation Bets on Feel‑Good, Non‑Alcoholic ‘Social Tonics’ With New Hiyo Partnership

Published: December 2, 2025 Live Nation is deepening its push into non‑alcoholic and “better‑for‑you” drinks, announcing a multi‑year partnership — and equity investment — in Hiyo Social Tonics that will bring the brand’s functional, alcohol‑free beverages to select venues and festivals across the United States. SSBCrack News The deal, first detailed in a Live Nation newsroom release and quickly picked…
2 December 2025
CapitaLand Investment Limited (SGX: 9CI) Stock: Q3 2025 Results, New Funds, Merger Talk and Analyst Forecasts to 2026

CapitaLand Investment Limited (SGX: 9CI) Stock: Q3 2025 Results, New Funds, Merger Talk and Analyst Forecasts to 2026

CapitaLand Investment Limited (CLI), the Temasek‑backed real estate investment manager listed on the Singapore Exchange under ticker 9CI, is ending 2025 in a curious position: the business is leaning harder into fee income and global funds, analysts overwhelmingly rate the stock a “buy”, yet the share price is still trudging along in the lower half of its trading range. As…
2 December 2025
····
Keppel Ltd (SGX: BN4) Near Record Highs: Earnings Jump, M1 Sale and Buybacks Drive 2025 Outlook

Keppel Ltd (SGX: BN4) Near Record Highs: Earnings Jump, M1 Sale and Buybacks Drive 2025 Outlook

As of 2 December 2025, Keppel Ltd (SGX: BN4) is trading close to its all‑time high, capping a year of strong earnings growth, aggressive asset monetisation and heavy share buybacks. At around S$10.20–S$10.25 in midday trading, Keppel’s share price is up about 52% over the past 12 months, giving the Singapore-listed asset manager and operator a market capitalisation of roughly…
2 December 2025
····
1 … 653 654 655 656 657 … 711

Stock Market Today

  • Is Stryker (SYK) Overvalued After Recent Share Price Drop?
    January 24, 2026, 7:19 PM EST. Stryker's shares slipped 9.1% over the past year but show strong gains of 43.8% over three years and 69.1% over five years. The medical technology firm's stock closed at $355.04, prompting debate on whether it prices in too much optimism. A Discounted Cash Flow (DCF) analysis estimates intrinsic value at $298.65 per share, suggesting the stock trades at an 18.9% premium and is overvalued on this metric. Other valuation checks yield mixed signals, with Stryker scoring 1 out of 6 indicating undervaluation in only one measure. Investors continue to balance its long-term healthcare role against current pricing, contributing to short-term weakness amid solid multi-year returns. The mixed valuation results highlight ongoing uncertainty about the stock's fair value amid evolving growth prospects and risk assessments.
Go toTop